Mologen extends clinical study to include another dosing group
The cancer drug MGN1703 is a DNA-based immune modulator that is being developed for immune therapy with patients who have solid tumours.
Since the patients' response to the innovative new cancer drug in the phase I clinical study has exceeded all expectations, the Management Board of the company took a decision in May to extend the study to include another dosing group. The additional amounts of the cancer drug MGN1703 needed for this purpose have in the meantime been produced, filled and packaged.
The preliminary evaluation of its effectiveness and its positive safety profile indicate that MGN1703 has high potential to at least stabilise the basic illness in the form of an advanced solid tumour with the patient population selected: more than 40 per cent of the patients were in a stable condition after completion of the 6-week course of treatment.
Mologen AG is currently making intensive preparations for additional clinical studies, in which the effectiveness of MGN1703 will be investigated. Phase 2 of the clinical study on patients with colorectal cancer is scheduled to start this year.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.